Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These data clearly indicate that the expression of the ANP gene in the ventricle is augmented in the failing heart in accordance with the severity of heart failure.
|
2521342 |
1989 |
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Mechanisms of sodium retention in heart failure: relation to the renin-angiotensin-aldosterone system.
|
1647690 |
1991 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have indicated that the serum level and ventricular expression of the ANP gene were augmented in patients with heart failure.
|
1535030 |
1992 |
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
The effect of early converting enzyme inhibition on neurohumoral activation in acute myocardial infarction.
|
8112904 |
1993 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In BIO14.6 and BIO53.58 strains at this age, ventricular BNP and ANP gene expressions are augmented, and the plasma BNP concentration is elevated to 136 and 108 fmol/ml, respectively, three times greater than the elevated plasma ANP concentration, which well mimics changes of the plasma BNP and ANP concentrations in human heart failure.
|
8083346 |
1994 |
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
|
11136700 |
2001 |
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors.
|
16101196 |
2005 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The ScaI polymorphism of the ANP gene might be an important additive genetic factor influencing neurohormonal activation and disease progression in severe HF.
|
17890443 |
2007 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical trials have documented the benefits and risks of the use of synthetic ANP (Anaritide) and BNP (Nesiritide) for treating heart failure, renal failure, and hypertension.
|
20433683 |
2011 |
Heart failure
|
0.600 |
Therapeutic
|
disease |
RGD |
Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure.
|
23931972 |
2013 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In experimental early stage HF characterized with marked atrial fibrosis, ANP, BNP, and CNP mRNA, and protein concentrations were higher in HF LA but not HF LV compared with normals.
|
23152112 |
2013 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The atrium is the major site of ANP synthesis, which has been said to increase in heart failure as a result of increased production in the left ventricular (LV) myocardium.
|
24599027 |
2014 |
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Up-regulation was evident for muscle LIM protein (Mlp), desmin, and heart failure (natriuretic peptide A [Nppa], Nppb, and myosin heavy chain 6) and fibrosis (transforming growth factor beta 1, alpha-smooth muscle actin, osteopontin, and periostin) markers.
|
25541130 |
2014 |
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In mice with PPCM due to a cardiomyocyte-specific knockout of STAT3 (CKO) neither low nor high dose of recombinant Relaxin-2 (serelaxin, sRlx-LD: 30 µg/kg/day; sRlx-HD: 300 µg/kg/day) affected cardiac fibrosis, inflammation and heart failure but sRlx-HD increased capillary/cardiomyocyte ratio. sRlx-HD significantly increased heart/body weight ratio and cardiomyocyte cross-sectional area in postpartum CKO and wild-type mice without changing the foetal gene expression program (ANP or β-MHC). sRlx-HD augmented plasma Prolactin levels in both genotypes, which induced cardiac activation of STAT5.
|
28453725 |
2017 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast, levels of neprilysin (p<0.01), cGMP (p<0.001), and ANP (p<0.001) were higher in systolic dysfunction patients than controls and were the highest in patients with dHF.
|
30148170 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Functionally, knockdown of BRD4 greatly downregulated the NPPA and NPPB in vivo and in vitro, improved the hemodynamic and biometric parameters in rat with heart failure, as well as decreased the apoptosis occurrence.
|
29352508 |
2018 |
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Atrial and brain natriuretic peptides (ANP and BNP) are established diagnostic and prognostic markers in heart failure, but their utility in patients with advanced cancer is unclear.
|
31128228 |
2019 |